By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Afferent Pharmaceuticals 

2929 Campus Drive
Suite 230
San Mateo  California  94403  U.S.A.
Phone: 650-286-1276 Fax: 650-286-1833




Company News
Days After Judge Overturns Merck & Co. (MRK)-Gilead (GILD) Lawsuit, Merck Acquires Bay Area's Afferent Pharma for $1.2 Billion 6/10/2016 5:53:03 AM
Afferent Pharmaceuticals Presents Updated Positive Results With AF-219 From Phase IIB Chronic Cough Study At The 2016 American Thoracic Society International Conference 5/16/2016 10:43:27 AM
Afferent Pharmaceuticals Announces Presentations Of Chronic Cough Clinical Data And Hypertension Research For The Upcoming American Thoracic Society 2016 International Conference 4/25/2016 10:45:01 AM
Afferent Pharmaceuticals Advances Novel Molecule, AF-130, To Phase I Clinical Trial 12/8/2015 8:03:24 AM
Afferent Pharmaceuticals Expands Executive Leadership Team With Appointments Of Prabha N. Ibrahim, PhD, As Chief Technology Officer And Michelle Carpenter, JD, RAC, As Vice President, Regulatory Affairs And Project Management 11/19/2015 10:09:47 AM
Afferent Pharmaceuticals Announces Phase 2 Clinical Trial With AF-219 In Cough In Idiopathic Pulmonary Fibrosis (IPF) Patients 11/11/2015 11:34:00 AM
Afferent Pharmaceuticals Announces Positive Results In Phase 2b Chronic Cough Trial 9/28/2015 1:30:17 PM
Afferent Pharmaceuticals Raises $55 Million In Oversubscribed Crossover Financing 7/8/2015 8:22:45 AM
Afferent Pharmaceuticals Announces The Election Of Dr. Peter Hirth To The Company’s Board Of Directors 12/3/2014 8:45:11 AM
Afferent Pharmaceuticals Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency By 75% in Chronic Cough Is Published In The Lancet 11/25/2014 6:37:44 AM